AbbVie Inc. - stock earnings
ABBV Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| April 26, 2024 AfterMarket | 2.31 / 2.26 | - | - / 12.2 billion | - |
ABBV Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | 822.0 million USD | 14.3 billion USD |
| 2023Q3 | 1.8 billion USD | 13.9 billion USD |
| 2023Q2 | 2.0 billion USD | 13.9 billion USD |
| 2023Q1 | 239.0 million USD | 12.2 billion USD |
| 2022Q4 | 2.5 billion USD | 15.1 billion USD |
| 2022Q3 | 3.9 billion USD | 14.8 billion USD |
| 2022Q2 | 924.0 million USD | 14.6 billion USD |
| 2022Q1 | 4.5 billion USD | 13.5 billion USD |
| 2021Q4 | 4.0 billion USD | 14.9 billion USD |
| 2021Q3 | 3.2 billion USD | 14.3 billion USD |
| 2021Q2 | 766.0 million USD | 14.0 billion USD |
| 2021Q1 | 3.6 billion USD | 13.0 billion USD |
| 2020Q4 | 36.0 million USD | 13.9 billion USD |
| 2020Q3 | 2.3 billion USD | 12.9 billion USD |
| 2020Q2 | -738.0 million USD | 10.4 billion USD |
| 2020Q1 | 3.0 billion USD | 8.6 billion USD |
| 2019Q4 | 2.8 billion USD | 8.7 billion USD |
| 2019Q3 | 1.9 billion USD | 8.5 billion USD |
| 2019Q2 | 741.0 million USD | 8.3 billion USD |
| 2019Q1 | 2.5 billion USD | 7.8 billion USD |
| 2018Q4 | -1.8 billion USD | 8.3 billion USD |
| 2018Q3 | 2.7 billion USD | 8.2 billion USD |
| 2018Q2 | 2.0 billion USD | 8.3 billion USD |
| 2018Q1 | 2.8 billion USD | 7.9 billion USD |
| 2017Q4 | 52.0 million USD | 7.7 billion USD |
| 2017Q3 | 1.6 billion USD | 7.0 billion USD |
| 2017Q2 | 1.9 billion USD | 6.9 billion USD |
| 2017Q1 | 1.7 billion USD | 6.5 billion USD |
| 2016Q4 | 1.4 billion USD | 6.8 billion USD |
| 2016Q3 | 1.6 billion USD | 6.4 billion USD |
| 2016Q2 | 1.6 billion USD | 6.5 billion USD |
| 2016Q1 | 1.4 billion USD | 6.0 billion USD |
| 2015Q4 | 1.5 billion USD | 6.4 billion USD |
| 2015Q3 | 1.2 billion USD | 5.9 billion USD |
| 2015Q2 | 1.4 billion USD | 5.5 billion USD |
| 2015Q1 | 1.0 billion USD | 5.0 billion USD |
| 2014Q4 | -810.0 million USD | 5.5 billion USD |
| 2014Q3 | 506.0 million USD | 5.0 billion USD |
| 2014Q2 | 1.1 billion USD | 4.9 billion USD |
| 2014Q1 | 980.0 million USD | 4.6 billion USD |
| 2013Q4 | 1.1 billion USD | 5.1 billion USD |
| 2013Q3 | 964.0 million USD | 4.7 billion USD |
| 2013Q2 | 1.1 billion USD | 4.7 billion USD |
| 2013Q1 | 968.0 million USD | 4.3 billion USD |
| 2012Q4 | 1.5 billion USD | 5.2 billion USD |
| 2012Q3 | 1.6 billion USD | 4.5 billion USD |
| 2012Q2 | 1.3 billion USD | 4.5 billion USD |
| 2012Q1 | 883.3 million USD | 4.2 billion USD |
| 2011Q4 | 1.2 billion USD | 4.9 billion USD |
| 2011Q3 | 12.3 million USD | 4.4 billion USD |
| 2011Q2 | 1.5 billion USD | 4.3 billion USD |
| 2011Q1 | 723.2 million USD | 3.9 billion USD |
| 2010Q4 | 4.2 billion USD | 15.6 billion USD |
ABBV Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | 4.9 billion USD | 54.3 billion USD |
| 2022 | 11.8 billion USD | 58.1 billion USD |
| 2021 | 11.5 billion USD | 56.2 billion USD |
| 2020 | 4.6 billion USD | 45.8 billion USD |
| 2019 | 7.9 billion USD | 33.3 billion USD |
| 2018 | 5.7 billion USD | 32.8 billion USD |
| 2017 | 5.3 billion USD | 28.2 billion USD |
| 2016 | 6.0 billion USD | 25.6 billion USD |
| 2015 | 5.1 billion USD | 22.9 billion USD |
| 2014 | 1.8 billion USD | 20.0 billion USD |
| 2013 | 4.1 billion USD | 18.8 billion USD |
| 2012 | 5.3 billion USD | 18.4 billion USD |
| 2011 | 3.4 billion USD | 17.4 billion USD |
| 2010 | 4.2 billion USD | 15.6 billion USD |
| 2009 | 4.6 billion USD | 14.2 billion USD |
ABBV
List: Contenders
Price: $159.90
Dividend Yield: 0.04%
Forward Dividend Yield: 3.71%
Payout Ratio: 227.94%
Dividend Per Share: 6.20 USD
Earnings Per Share: 2.72 USD
P/E Ratio: 63.54
Exchange: NYQ
Sector: Healthcare
Industry: Drug Manufacturers - General
Volume: 6.2 million
Ebitda: 1.9 billionMarket Capitalization: 298.7 billion
Average Dividend Frequency: 4
Years Paying Dividends: 12
DGR3: 7.25%
DGR5: 8.27%
DGR10: 9.99%